Horizons Marijuana ETF (TSX:HMMJ): Best Way to Bet on a Cannabis Rebound?

Horizons Marijuana Life Sciences ETF (TSX:HMMJ) stock could be the ultimate proxy for a rebound in the legal pot sector.

| More on:
edit Jars of marijuana

Image source: Getty Images

Cannabis stocks have had a rough year. Investors in the sector have collectively lost billions of dollars, while the stocks are trading at their lowest valuations since 2017. Market sentiment has turned decisively pessimistic, which makes the sector fertile ground for contrarian investors. 

Value-oriented investors probably understand that the top players in this sector are gearing up for a better year ahead. The roll-out of Cannabis 2.0 products, the relaxation of licensing rules in Ontario, along with ongoing involvement of major established corporations like Constellation Brands and Altria, all indicate that the market could bounce back in 2020. 

However, I still believe it is way too risky to bet on any individual stock in this sector. Even the largest marijuana producers could face cash flow issues or debt-repayment problems that could drag them down, while the rest of the sector recovers and snatches away their market share. It’s simply too difficult to pick stocks with conviction here. 

Instead, I believe investors should take a pragmatic approach and invest in the broader market through an exchange-traded fund (ETF) like Horizons Marijuana Life Sciences ETF (TSX:HMMJ). Here are three reasons why betting on this ETF is better than trying to pick winners or losers in the Canadian marijuana sector in 2020

Diversification

The most obvious benefit of investing in an ETF rather than stock picking is the way risk is mitigated through diversification. HMMJ owns a stake in the top 55 publicly listed marijuana stocks. The exposure to these holdings is weighted by market capitalization, which means the industry leaders account for the biggest portion of the overall portfolio. 

This level of diversification also means that the downside is limited when any one company fails. CannTrust, for example, was a larger part of the portfolio at the start of 2019 but now accounts for a smaller fraction since its stock price plummeted. Meanwhile, the larger stocks that performed relatively better offset the losers. 

This makes the HMMJ ETF a barometre for the entire industry. In other words, it’s a bet on consumer demand for marijuana rather than the success of any individual company. 

Steady income

Another reason HMMJ is an ideal bet is the fact that it offers a dividend to shareholders. Admittedly, it’s surprising that a portfolio of money-losing companies pays a dividend, yet that seems to be the case. In fact, the trailing dividend yield is impressively high at 12.4%. 

Here’s the secret: HMMJ isn’t paying a dividend from the profits of its underlying stocks. Instead, the ETF management company generates income by lending the stocks to short-sellers and daily traders. The interest earned on this short-selling activity is passed onto investors in the form of dividends. 

In other words, HMMJ benefits from the market collapse as well.  

Fair value

Like any other ETF, HMMJ’s market price is usually misaligned with the net value of its underlying holdings. Generally, the ETF has traded at a discount to net asset value (NAV). However, at the moment it is trading at par with NAV. 

In other words, the ETF is fairly valued. However, you could wait for another discount to emerge to add exposure if you’re feeling adventurous. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends CannTrust Holdings, CannTrust Holdings Inc, and Constellation Brands. Fool contributor Vishesh Raisinghani has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Forget Canopy Growth: 1 Cannabis Stock With Far Less Risk

Cannabis stocks like Canopy Growth (TSX:WEED) haven't done well for quite some time, yet this one deserves a major boost!

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Canopy Growth Stock Worth Buying?

Canopy Growth stock (TSX:WEED) made a big move to consolidate its shares, but will this help the company move forward?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Corp: Will it Ever Be a Buy?

Canopy Growth Corp (TSX:WEED) keeps going lower. Will it ever find a bottom?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks a Good Buy in November 2023?

Cannabis stocks have slumped a long way down in the last few years, so is November the time to get…

Read more »

A cannabis plant grows.
Cannabis Stocks

2 Top Cannabis Stocks to Buy on the TSX Today

Two cannabis stocks are the top picks as the market moves toward consolidation and stability.

Read more »